



#6 P3  
10/10/02

Patent  
Attorney's Docket No. 017753-137

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:	)	
	)	
Etienne REGULIER <i>et al.</i>	)	Group Art Unit: 1632
	)	
Application No.: 09/762,573	)	Examiner: Liping Chen
	)	
Filed: February 8, 2001	)	Confirmation No.: 5075
	)	
For: COMPOSITION FOR	)	
IMPLEMENTING A CYTOTOXIC, IN	)	
PARTICULAR AN ANTITUMORAL OR	)	
ANTIVIRAL TREATMENT IN A MAMMAL	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Response to Restriction Requirement is in complete response to the Official Action (Restriction Requirement) mailed on August 5, 2002 (Paper No. 4). A one-month Extension of Time is filed herewith, extending the due date to October 7, 2002 (October 5, 2002 falls on a Saturday).

The Examiner has required the election of a single Group, pursuant to PCT Rule 13.1. Applicants hereby elect, with traverse, Group II (*i.e.*, claims 1-21, and 24-47), drawn to drawn to a composition comprising a) a nucleic acid sequence encoding all or part of an MIP chemokine and b) at least one nucleic acid sequence encoding all or part of a cytokine having at least cytotoxic activity, a vector, a formulation, and a method of treating a patient in need.

With regard to a species, Applicants hereby elect, with traverse, interleukin-2 (IL-2), for purposes of examination.

**RECEIVED**

OCT 10 2002

**TECH CENTER 1600/2900**